These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 26506004

  • 1. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
    Price KE, Orazi G, Ruoff KL, Hebert WP, O'Toole GA, Mastoridis P.
    PLoS One; 2015; 10(10):e0141192. PubMed ID: 26506004
    [Abstract] [Full Text] [Related]

  • 2. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, Ulrich M, Molin S, Riethmüller J, Döring G.
    J Infect Dis; 2010 Nov 15; 202(10):1585-92. PubMed ID: 20942647
    [Abstract] [Full Text] [Related]

  • 3. Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System.
    Price KE, Naimie AA, Griffin EF, Bay C, O'Toole GA.
    J Bacteriol; 2016 Jan 15; 198(2):237-47. PubMed ID: 26483523
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF, Zhang H, Tewes F, Leal J, Smyth HDC.
    Mol Pharm; 2018 Apr 02; 15(4):1643-1652. PubMed ID: 29514003
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, Macleod C, Aaron SD, Harbour C.
    J Clin Microbiol; 2005 Oct 02; 43(10):5085-90. PubMed ID: 16207967
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M, Traore H, El Manssouri N, Vanderbist F, Vaneechoutte M, Devleeschouwer MJ.
    Int J Antimicrob Agents; 2009 Oct 02; 34(4):370-4. PubMed ID: 19505804
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms.
    Barraud N, Buson A, Jarolimek W, Rice SA.
    PLoS One; 2013 Oct 02; 8(12):e84220. PubMed ID: 24349568
    [Abstract] [Full Text] [Related]

  • 12. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR, White A, Elborn JS, Tunney MM.
    Eur J Clin Microbiol Infect Dis; 2005 Oct 02; 24(10):677-87. PubMed ID: 16249934
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
    Howlin RP, Cathie K, Hall-Stoodley L, Cornelius V, Duignan C, Allan RN, Fernandez BO, Barraud N, Bruce KD, Jefferies J, Kelso M, Kjelleberg S, Rice SA, Rogers GB, Pink S, Smith C, Sukhtankar PS, Salib R, Legg J, Carroll M, Daniels T, Feelisch M, Stoodley P, Clarke SC, Connett G, Faust SN, Webb JS.
    Mol Ther; 2017 Sep 06; 25(9):2104-2116. PubMed ID: 28750737
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J, Abdelghany SM, Quinn DJ, Schmid D, Megaw J, Donnelly RF, Jones DS, Kissenpfennig A, Elborn JS, Gilmore BF, Taggart CC, Scott CJ.
    J Control Release; 2015 Jan 28; 198():55-61. PubMed ID: 25481442
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O, Tolker-Nielsen T, Jensen PØ, Wang H, Høiby N.
    Adv Drug Deliv Rev; 2015 May 28; 85():7-23. PubMed ID: 25477303
    [Abstract] [Full Text] [Related]

  • 18. The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability.
    Moreau-Marquis S, Bomberger JM, Anderson GG, Swiatecka-Urban A, Ye S, O'Toole GA, Stanton BA.
    Am J Physiol Lung Cell Mol Physiol; 2008 Jul 28; 295(1):L25-37. PubMed ID: 18359885
    [Abstract] [Full Text] [Related]

  • 19. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
    Vazquez-Espinosa E, Marcos C, Alonso T, Giron RM, Gomez-Punter RM, Garcia-Castillo E, Zamora E, Cisneros C, Garcia J, Valenzuela C, Ancochea J.
    Expert Rev Anti Infect Ther; 2016 Jul 28; 14(1):9-17. PubMed ID: 26559549
    [Abstract] [Full Text] [Related]

  • 20. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates.
    Moriarty TF, Elborn JS, Tunney MM.
    Br J Biomed Sci; 2007 Jul 28; 64(3):101-4. PubMed ID: 17910277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.